EGFR and lung cancer: This case highlights ivonescimab’s dual-mechanism potential to overcome resistance in EGFR-mutant Non–small cell lung cancer (NSCLC) by concurrently alleviating PD-1-mediated immunosuppression and VEGF-driven angiogenesis.